DE3918543C2 - - Google Patents

Info

Publication number
DE3918543C2
DE3918543C2 DE3918543A DE3918543A DE3918543C2 DE 3918543 C2 DE3918543 C2 DE 3918543C2 DE 3918543 A DE3918543 A DE 3918543A DE 3918543 A DE3918543 A DE 3918543A DE 3918543 C2 DE3918543 C2 DE 3918543C2
Authority
DE
Germany
Prior art keywords
naftopidil
naphth
methoxyphenyl
piperazine
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3918543A
Other languages
German (de)
English (en)
Other versions
DE3918543A1 (de
Inventor
Gisbert Dr.Med.Vet. 6941 Laudenbach De Sponer
Ulrich 6945 Hirschberg De Reicke
Michael Dr.Phil. 8132 Tutzing De Nelboeck-Hochstetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6382247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3918543(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to DE3918543A priority Critical patent/DE3918543A1/de
Priority to PH40616A priority patent/PH26690A/en
Priority to CA002017619A priority patent/CA2017619C/en
Priority to US07/530,362 priority patent/US5026706A/en
Priority to AT90110207T priority patent/ATE84416T1/de
Priority to DK90110207.9T priority patent/DK0401653T3/da
Priority to ES90110207T priority patent/ES2054147T3/es
Priority to EP90110207A priority patent/EP0401653B1/de
Priority to DE9090110207T priority patent/DE59000748D1/de
Priority to JP2144272A priority patent/JPH062673B2/ja
Priority to IL9460190A priority patent/IL94601A/en
Priority to PT94268A priority patent/PT94268B/pt
Priority to AU56282/90A priority patent/AU625766B2/en
Priority to NZ245673A priority patent/NZ245673A/en
Priority to HU903515A priority patent/HU206976B/hu
Priority to DD90341372A priority patent/DD294864A5/de
Priority to ZA904338A priority patent/ZA904338B/xx
Priority to IE201490A priority patent/IE62937B1/en
Priority to KR1019900008320A priority patent/KR0131452B1/ko
Publication of DE3918543A1 publication Critical patent/DE3918543A1/de
Publication of DE3918543C2 publication Critical patent/DE3918543C2/de
Application granted granted Critical
Priority to GR920403077T priority patent/GR3007328T3/el
Priority to HK46996A priority patent/HK46996A/xx
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE3918543A 1989-06-07 1989-06-07 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie Granted DE3918543A1 (de)

Priority Applications (21)

Application Number Priority Date Filing Date Title
DE3918543A DE3918543A1 (de) 1989-06-07 1989-06-07 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
PH40616A PH26690A (en) 1989-06-07 1990-05-04 Method for treating dysuria using naftpidil
CA002017619A CA2017619C (en) 1989-06-07 1990-05-28 Use of naftopidil for the therapy of dysuria in cases of benign prostatic hypertrophy
US07/530,362 US5026706A (en) 1989-06-07 1990-05-30 Method for treating dysuria using naftopidil
AT90110207T ATE84416T1 (de) 1989-06-07 1990-05-30 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hyperthrophie.
DK90110207.9T DK0401653T3 (da) 1989-06-07 1990-05-30 Anvendelse af naftopidil til terapi af dysuri ved godartet prostata-hypertrofi
ES90110207T ES2054147T3 (es) 1989-06-07 1990-05-30 Utilizacion de naftopidil para la terapia de la disuria en el caso de hipertrofia benigna de la prostata.
EP90110207A EP0401653B1 (de) 1989-06-07 1990-05-30 Verwendung von Naftopidil zur Therapie der Dysurie bei benigner Prostata-Hyperthrophie
DE9090110207T DE59000748D1 (de) 1989-06-07 1990-05-30 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hyperthrophie.
JP2144272A JPH062673B2 (ja) 1989-06-07 1990-06-01 良性前立腺肥大における排尿困難症を治療するためのナフトピジルの用途
IL9460190A IL94601A (en) 1989-06-07 1990-06-03 Pharmaceutical preparations containing neptofidil for the treatment of dysuria
PT94268A PT94268B (pt) 1989-06-07 1990-06-05 Processo para a preparacao de composicoes farmaceuticas contendo naftopidil para a terapia de disuria na hipertrofia benigna da prostata
AU56282/90A AU625766B2 (en) 1989-06-07 1990-06-05 The use of naftpidil for the therapy of dysuria in cases of benign prostatic hypertrophy
NZ245673A NZ245673A (en) 1989-06-07 1990-06-05 Use of naftopidil [ie 1-(2-methoxyphenyl)-4-[3-(naphth-1-yloxy)-2-hydroxypropyl]piperazine] to prepare a medicament for the treatment of dysuria
IE201490A IE62937B1 (en) 1989-06-07 1990-06-06 The use of naftopidil for the therapy of dysuria in cases of benign prostatic hypertrophy
DD90341372A DD294864A5 (de) 1989-06-07 1990-06-06 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
ZA904338A ZA904338B (en) 1989-06-07 1990-06-06 The use of naftpidil for the therapy of dysuria in cases of benign prostatic hypertrophy
HU903515A HU206976B (en) 1989-06-07 1990-06-06 Process for producing pharmaceutical compositions comprising naphthopydil, for treating diuria
KR1019900008320A KR0131452B1 (ko) 1989-06-07 1990-06-07 양성 전립선 비대증 경우의 배뇨장애 치료용 나프토피딜
GR920403077T GR3007328T3 (esLanguage) 1989-06-07 1993-03-12
HK46996A HK46996A (en) 1989-06-07 1996-03-14 Use of naftopidil for the treatment of dysuria caused by benign prostate hypertrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3918543A DE3918543A1 (de) 1989-06-07 1989-06-07 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie

Publications (2)

Publication Number Publication Date
DE3918543A1 DE3918543A1 (de) 1990-12-13
DE3918543C2 true DE3918543C2 (esLanguage) 1991-06-06

Family

ID=6382247

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3918543A Granted DE3918543A1 (de) 1989-06-07 1989-06-07 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
DE9090110207T Expired - Fee Related DE59000748D1 (de) 1989-06-07 1990-05-30 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hyperthrophie.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE9090110207T Expired - Fee Related DE59000748D1 (de) 1989-06-07 1990-05-30 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hyperthrophie.

Country Status (19)

Country Link
US (1) US5026706A (esLanguage)
EP (1) EP0401653B1 (esLanguage)
JP (1) JPH062673B2 (esLanguage)
KR (1) KR0131452B1 (esLanguage)
AT (1) ATE84416T1 (esLanguage)
AU (1) AU625766B2 (esLanguage)
CA (1) CA2017619C (esLanguage)
DD (1) DD294864A5 (esLanguage)
DE (2) DE3918543A1 (esLanguage)
DK (1) DK0401653T3 (esLanguage)
ES (1) ES2054147T3 (esLanguage)
GR (1) GR3007328T3 (esLanguage)
HK (1) HK46996A (esLanguage)
HU (1) HU206976B (esLanguage)
IE (1) IE62937B1 (esLanguage)
IL (1) IL94601A (esLanguage)
PH (1) PH26690A (esLanguage)
PT (1) PT94268B (esLanguage)
ZA (1) ZA904338B (esLanguage)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
EP1832598A3 (en) 1999-09-30 2008-01-02 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
BR102012000187A2 (pt) * 2012-01-05 2018-04-10 Univ Rio De Janeiro Derivados n-fenilpiperazínicos antagonistas de adrenoceptores a1a, a1d e de receptores 5-ht1a no tratamento da hiperplasia prostática benigna, composições farmacêuticas contendo os mesmos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL175059C (nl) * 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.

Also Published As

Publication number Publication date
HUT54494A (en) 1991-03-28
IL94601A0 (en) 1991-04-15
GR3007328T3 (esLanguage) 1993-07-30
ES2054147T3 (es) 1994-08-01
DD294864A5 (de) 1991-10-17
PT94268B (pt) 1997-01-31
KR910000152A (ko) 1991-01-29
DK0401653T3 (da) 1993-03-29
ATE84416T1 (de) 1993-01-15
ZA904338B (en) 1991-03-27
EP0401653B1 (de) 1993-01-13
CA2017619C (en) 1995-06-20
PH26690A (en) 1992-09-15
DE59000748D1 (de) 1993-02-25
JPH0324014A (ja) 1991-02-01
JPH062673B2 (ja) 1994-01-12
IE62937B1 (en) 1995-03-08
PT94268A (pt) 1991-02-08
IE902014L (en) 1990-12-07
HK46996A (en) 1996-03-22
KR0131452B1 (ko) 1998-04-17
AU5628290A (en) 1990-12-13
IL94601A (en) 1994-06-24
DE3918543A1 (de) 1990-12-13
EP0401653A3 (de) 1991-07-17
AU625766B2 (en) 1992-07-16
CA2017619A1 (en) 1990-12-07
HU206976B (en) 1993-03-01
HU903515D0 (en) 1990-10-28
US5026706A (en) 1991-06-25
EP0401653A2 (de) 1990-12-12

Similar Documents

Publication Publication Date Title
EP0143977B1 (de) Bilobalid zur Anwendung als Therapeutischer Wirkstoff
DE69133348T2 (de) Behandlung von nicht-entzündlichen darmerkrankungen
EP2072054B1 (de) Verwendung eines Extraktes aus Blättern von Ginkgo biloba
Parascandola Chaulmoogra oil and the treatment of leprosy
DE19737348C2 (de) Neue Clindamycin und Clotrimazol enthaltende pharmazeutische Zusammensetzung
DE69420776T2 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE3883606T2 (de) Verwendung von Fluoxetin zur Behandlung des Diabetes.
DE3918543C2 (esLanguage)
DE4214953A1 (de) Arzneimittel zur Erhöhung des Testosteronspiegels
DE2824165A1 (de) Arzneimittel mit angstneurosen und angstaehnliche neurosen beseitigender wirkung und verfahren zum zubereiten des arzneimittels
EP0618797B1 (de) Bilobalid enthaltende pharmazeutische zubereitungen zur behandlung von spannungs- und angstzuständen
DE19726871C1 (de) Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
DE3213091A1 (de) Verwendung von femoxetin oder einem pharmazeutisch vertraeglichen salz davon zur steuerung und verminderung von appetit und gewicht
DE1917283C3 (de) Herstellung antimikrobieller Präparate
DD242749A5 (de) Verbesserte entzuendungshemmende zusammensetzungen und verfahren
DE19716660A1 (de) Zubereitungen, insbesondere pharmazeutische, und Arzneiformen auf pflanzlicher Basis zur Bekämpfung von Heliobacter pylori-Infektionen
DE69005909T2 (de) Mischung von Vitamin A in physiologischer Dosis und verschiedenen Wirkstoffen mit therapeutischer Wirksamkeit.
DE69936773T2 (de) Behandlung von depression und zusammensetzungen dazu
DE2015877C3 (de) Arzneimittel zur Behandlung der Prostatahypertrophie
DE3511236C2 (esLanguage)
DE2334358A1 (de) Pharmazeutische zubereitungen mit neuartiger wirkung
DE3129714A1 (de) Anti-psychotikum
DE2505913A1 (de) Arzneimittel zur oralen behandlung von nicht-tumorartigen gastroduodenalbeschwerden und verfahren zu seiner herstellung
DE4206375A1 (de) Arzneimittel zur behandlung von morbus alzheimer
Kloke Die neu standardisierte Morphinlösung NRF 2.4 zur Dosisfindung bei Ersteinstellung mit Morphin und als Zusatzmedikation bei einer Basistherapie mit retardierten Morphinsulfattabletten

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee